Testing CB03-154 for adults with focal epilepsy
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have been diagnosed with focal epilepsy for at least 2 years.
- You must be on a stable dose of 1 to 3 anti-seizure medications for at least one month before the study starts.
- You must have had at least 6 focal seizures (without a long-lasting seizure emergency) in the past few months.
- You must be able to keep a daily seizure diary.
- Women who can become pregnant must use highly effective birth control, and men must also use birth control if their partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term follow-up for people with epilepsy who already completed a previous trial of the drug CB03-154. It checks if the drug remains safe and effective over more time.
This study tests a new medicine called BHV-7000 for adults whose focal seizures (starting in one part of the brain) are not controlled by current treatments. The goal is to see if it can reduce seizures safely.
This study tests whether a new medication called RAP-219 can help adults with focal seizures (seizures that start in one area of the brain) control their seizures better. You would take this medication alongside your current seizure drugs for about 12 weeks.
This study tests a new medication called RAP-219 to see if it can reduce seizure frequency in adults with focal epilepsy (seizures starting in one area of the brain). You'll take the medication alongside your current seizure drugs and track your seizures daily using an app.
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
Hear when a new Focal Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.